hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06323980 id: DSM202108 briefTitle: INHANCE Stemless Reverse Shoulder IDE overallStatus: NOT_YET_RECRUITING date: 2024-09-15 date: 2027-11-10 date: 2028-04-10 date: 2024-03-21 date: 2024-04-24 name: DePuy Orthopaedics class: INDUSTRY briefSummary: 2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder. conditions: Arthroplasty conditions: Replacement conditions: Shoulder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 2:1 Randomized (Stemless to Stemmed) primaryPurpose: TREATMENT masking: NONE count: 168 type: ESTIMATED name: Reverse Total Shoulder measure: Constant Murley Score (CMS) measure: Removal of any system component measure: Revision of any system component measure: Reoperation of any system component measure: Supplemental Fixation of any system component measure: Radiolucent Lines (Humeral & Glenoid) measure: Migration and Tilt (Humeral & Glenoid) measure: Constant Murley Score (CMS) measure: EQ-5D-5L and EQ-VAS measure: Simple Shoulder Test measure: Single Assessment Numeric Evaluation (SANE) Score measure: Survivorship measure: Complications measure: Constant Murley Score (CMS) measure: EQ-5D-5L and EQ-VAS measure: Simple Shoulder Test measure: Single Assessment Numeric Evaluation (SANE) Score measure: Range of Motion sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hoag Orthopedic Institute city: Irvine state: California zip: 92618 country: United States lat: 33.66946 lon: -117.82311 facility: Atlantis Orthopaedics city: Lake Worth state: Florida zip: 33463 country: United States lat: 26.61708 lon: -80.07231 facility: Boston Sports & Shoulder Center city: Waltham state: Massachusetts zip: 02451 country: United States lat: 42.37649 lon: -71.23561 facility: Trinity Health Grand Rapids city: Grand Rapids state: Michigan zip: 49503 country: United States lat: 42.96336 lon: -85.66809 facility: Missouri Orthopaedic Institute (MOI) city: Columbia state: Missouri zip: 65201 country: United States lat: 38.95171 lon: -92.33407 facility: Lindner Research Center city: Cincinnati state: Ohio zip: 45219 country: United States lat: 39.12713 lon: -84.51435 facility: Cleveland Clinic city: Cleveland state: Ohio zip: 44195 country: United States lat: 41.4995 lon: -81.69541 facility: Slocum Center for Orthpaedics and Sports Medicine city: Eugene state: Oregon zip: 97401 country: United States lat: 44.05207 lon: -123.08675 facility: Rothman Orthopaedics Institute city: Philadelphia state: Pennsylvania zip: 19107 country: United States lat: 39.95233 lon: -75.16379 facility: TOSH- The Orthopedic Specialty Hospital city: Murray state: Utah zip: 84107 country: United States lat: 40.66689 lon: -111.88799 facility: University of Utah city: Salt Lake City state: Utah zip: 84108 country: United States lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06323967 id: 231981 briefTitle: Growing Strong Study of Unconditional Cash Transfers Plus Peer Support for Families With Babies in Homeless Shelters overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-03 date: 2027-03 date: 2024-03-21 date: 2024-03-21 name: Vanderbilt University class: OTHER name: Women in Need (Win) name: The Samuels Group name: New York City Center for Innovation through Data Intelligence (CIDI) briefSummary: The Growing Strong program tests a novel approach to helping families with young children living in homeless shelters, namely offering guaranteed, unconditional cash gifts that families can use as they wish plus voluntary peer support. The assumption behind this approach is that families know best how to allocate resources to meet their own individual needs. While there are a number of Direct Cash Transfer studies taking place around the country, the investigator(s) are unaware of any that have tested the relationship of receiving cash on homelessness among families specifically. To be eligible to participate in the study, families must reside in a homeless shelter and have at least one child under two years of age living with them in shelter. The investigator(s) have tied eligibility to the age of the youngest child in the household because rates of shelter use are highest among this population and because the costs associated with young children increase such families' financial burdens.
A total of 200 families will be enrolled in the study. One hundred families in the active intervention group will receive $1,500 per month ("substantial cash") for 24 months ($18,000 annually) and may also elect to receive peer support services. One hundred families in the active comparison group will receive $50 per month ("nominal cash") for 24 months ($600 annually) and will not have access to the peer support services. A third, passive comparison group will receive usual care within the homeless shelter system in the same metropolitan area (New York City) as participants in both cash gift groups. This group of families will be followed only in administrative records.
nctId: NCT06323954 id: H24110 briefTitle: tVNS During Motor Training in Older Adults overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2026-05-31 date: 2026-06-30 date: 2024-03-21 date: 2024-04-01 name: Georgia Institute of Technology class: OTHER name: University of Florida briefSummary: The goal of this study is to learn about the effect of applying transcutaneous vagus nerve stimulation (tVNS) during motor training on motor learning in older adults. The main question it aims to answer is whether applying tVNS after successful motor trials (post-success tVNS) will facilitate the rate of motor learning. Participants will be randomly assigned to tVNS or sham group and receive tVNS or sham, respectively, at the outer ear during finger control training sessions. Finger control performance will be tested before and after the training sessions without outer ear stimulation. conditions: Older Adults studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 32 type: ESTIMATED name: tVNS stimulation name: Sham stimulation measure: Rate of error reduction sex: ALL minimumAge: 65 Years maximumAge: 84 Years stdAges: OLDER_ADULT facility: Human Neuromuscular Physiology Lab city: Atlanta state: Georgia zip: 30332 country: United States name: Minoru Shinohara, Ph.D. role: CONTACT phone: 404-894-1030 email: shinohara@gatech.edu name: Minoru Shinohara, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06323941 id: UV0003 briefTitle: Motor Imagery and Isometric Exercises on Pelvic Floor Sensorimotor Condition overallStatus: COMPLETED date: 2023-11-01 date: 2024-03-01 date: 2024-03-14 date: 2024-03-21 date: 2024-03-22 name: University of Valencia class: OTHER briefSummary: Mental practice (both in isolation and also in combination with real practice) has been shown to improve somatosensory and motor variables but so far no study has taken it into the study of women's health. Through the present study the investigators want to offer some interesting data regarding the effectiveness of mental practice combined with physical practice. conditions: Isometric Exercise conditions: Motor Imagery conditions: Women's Health studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 30 type: ACTUAL name: Motor Imagery plus therapeutic exercise name: Therapeutic exercises measure: Skin conductance (for asessing electrodermal activity) measure: Algometry for assessing pressure pain thresholds (Pain sensitivity) measure: maximal pelvic floor muscle strength (measured in grams and with the phenix device) sex: FEMALE minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Ferran Cuenca Martínez city: Valencia zip: 46017 country: Spain lat: 39.46975 lon: -0.37739 hasResults: False
nctId: NCT06323928 id: 20297A id: 2023-508821-28-00 type: OTHER domain: EU Trial briefTitle: A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments acronym: PROCEED overallStatus: RECRUITING date: 2024-04-01 date: 2025-07-31 date: 2025-09-30 date: 2024-03-21 date: 2024-04-17 name: H. Lundbeck A/S class: INDUSTRY briefSummary: The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 2 to 4 other available medications to prevent their migraines, but these medications have not helped them. conditions: Migraine studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 498 type: ESTIMATED name: Lu AG09222 name: Placebo measure: Change From Baseline in the Number of Monthly Migraine Days (MMDs) measure: Change From Baseline in MMDs measure: Percentage of Participants With ≥50% Reduction From Baseline in MMDs measure: Percentage of Participants With ≥75% Reduction From Baseline in MMDs measure: Change from Baseline in the Number of Monthly Headache Days measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs) measure: Number of Participants with Anti-drug Antibodies (ADA) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Accellacare of Charleston status: RECRUITING city: Mount Pleasant state: South Carolina zip: 29464 country: United States lat: 32.79407 lon: -79.86259 hasResults: False
nctId: NCT06323915 id: 2020_03_C3M briefTitle: Comparative Study of 3 Multifocal Intraocular Lenses in Murcia acronym: C3M overallStatus: RECRUITING date: 2021-04-20 date: 2025-06-20 date: 2025-09-20 date: 2024-03-21 date: 2024-03-21 name: Cristalens Industrie class: INDUSTRY briefSummary: The goal of this clinical trial is to compare the performance of 3 intraocular lenses (IOLs): FineVision (comparator), ARTIS SYMBIOSE (study lenses), and Tecnis Synergy (comparator) through binocular distance-corrected defocus curve.
Participants will attend a total of 5 study visits: 1 preoperative visit, 1 surgery visit and 3 postoperative visits. conditions: Cataract studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 84 type: ESTIMATED name: intraocular lens implantation in cataract surgery measure: defocus curve comparison sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vista Clinic Ircovision Murcia status: RECRUITING city: Murcia zip: 30008 country: Spain name: Juan Zapata role: CONTACT phone: +34 968 27 17 35 email: juanf.zapata.diaz@gmail.com lat: 37.98704 lon: -1.13004 hasResults: False
nctId: NCT06323902 id: PT-CO39 briefTitle: Autologous Platelet-rich Plasma as a Treatment for Macular Holes overallStatus: COMPLETED date: 2022-10-25 date: 2023-06-08 date: 2024-02-29 date: 2024-03-21 date: 2024-03-21 name: Clinica Oftalmologica Paredes class: OTHER briefSummary: For a series of patients with full-thickness macular hole, an autologous plasma rich in growth factors was developed in the form of a clot and applied to the retinal defect. These patients were followed up for a period of one year, obtaining substantial improvement both anatomically and functionally. conditions: Macular Holes conditions: Macular Hole of Left Eye (Disorder) conditions: Macular Hole of Right Eye (Disorder) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 13 type: ACTUAL name: Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation measure: Macular hole closure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinica Ofalmologica Paredes city: Pasto state: Nariño zip: 520002 country: Colombia lat: 1.21361 lon: -77.28111 hasResults: False
nctId: NCT06323889 id: LIMITFOOD2 briefTitle: Longitudinal Monitoring During Intermittent Fasting Protocols in Obese Adults acronym: LIMITFOOD2 overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-01 date: 2027-01 date: 2024-03-21 date: 2024-04-19 name: University of Zurich class: OTHER briefSummary: LIMITFOOD2 is a randomized clinical intervention study that investigates the effects of two different intermittent fasting protocols compared to a control group on the health of obese adults. A total of 90 participants will be randomized into three equally sized groups: a modified alternate day fasting, a time-restricted eating and a control group, receiving general weight-loss counseling. conditions: Intermittent Fasting conditions: Obesity conditions: Time Restricted Eating studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: Modified Alternate Day Fasting name: Time-Restricted Eating name: Weight-loss counseling measure: Fat Volume measure: Distribution of fat volume measure: Concentration of Leptin measure: Changes in Insulin Sensitivity measure: Changes in Fasting Lipids measure: Changes in Inflammatory Markers measure: Free triiodothyronine (fT3) measure: Correlation of longitudinally measured parameters measure: Serum Metabolomics measure: Genetic Analysis measure: LDL Particle Size measure: Fecal Microbiome sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Department of Endocrinology, Diabetology and Clinical Nutrition city: Zürich zip: 8091 country: Switzerland lat: 47.36667 lon: 8.54999 hasResults: False
nctId: NCT06323876 id: HSR301252 id: R01HL171918 type: NIH link: https://reporter.nih.gov/quickSearch/R01HL171918 briefTitle: The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-05 date: 2029-05 date: 2024-03-21 date: 2024-03-21 name: University of Virginia class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: This observational study involves obtaining 2 chest CT scans; a historical baseline CT within ±1 year of enrollment into PRECISIONS, and a follow-up CT (either historical or prospective) 12 months ± 180 days after the baseline CT. Many IPF patients will have a CT scan every 12 months for disease monitoring and cancer screening. Participants will have the option to share historical CTs only or they can choose to have a research CT done for the follow-up scan, if a scan for clinical purposes is not available. conditions: Idiopathic Pulmonary Fibrosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 160 type: ESTIMATED name: HRCT name: Blood Draw measure: Derivation of DTA in IPF only cases from the PFF-PR and its associations with disease severity and outcomes. measure: Determine whether known IPF-risk genetic variants are associated with DTA score. measure: Identify novel genetic variants that associate with DTA score progression. measure: Determine if DTA or any constituent radiomic features correlate with select plasma proteins. measure: Determine if DTA or any of constituent radiomic features correlate with transcriptomic measure: Determine the best combination of markers (DTA, proteins and transcriptome) for machine learning algorithms for AUC evaluation of ROCs on all 3 cohorts. measure: Determine associations of changes in DTA scores with 12-month changes in FVC and DLCO. measure: Determine associations of changes in DTA scores with drug treatment (i.e., antifibrotics) sex: ALL minimumAge: 40 Years maximumAge: 101 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323863 id: N°4-RCB/EUDRACT briefTitle: Ultra-high Resolution CT: the End of Stapes Prosthesis Measurement Misestimation overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-06-01 date: 2024-12-01 date: 2024-03-21 date: 2024-03-21 name: Central Hospital, Nancy, France class: OTHER briefSummary: Actual CT scanners overestimate stapes piston size, and do not represent a valuable technique for their follow-up, especially in case of complication. Ultra-high resolution has not yet been evaluated in this setting. conditions: Otosclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 20 type: ESTIMATED name: stapedectomy name: ultra high resolution CT measure: length sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chu Nancy city: Nancy zip: 54000 country: France name: romain gillet, md role: CONTACT phone: 00383851811 email: r.gillet@chru-nancy.fr lat: 48.68439 lon: 6.18496 hasResults: False
nctId: NCT06323837 id: 20383 briefTitle: Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment acronym: MIRROM overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2026-04-01 date: 2024-03-21 date: 2024-03-21 name: Washington State University class: OTHER briefSummary: This project will evaluate the ability of Mirtazapine (MZP), a pharmacologically unique medication with a growing body of evidence to support its efficacy and safety for the treatment of methamphetamine (MA) use among medication for opioid use disorder (MOUD) patients, to significantly decrease MA use and related health-impairing behaviors. MZP has already successfully been used in the treatment of methamphetamine (detailed further below and in the Appendices).
The investigators hypothesize that those assigned to the MZP plus treatment as usual (TAU) MZP+TAU arm will demonstrate significantly increased rates of biochemically verified abstinence from MA and other substances of abuse and experience improvements in health impairing behaviors relative to the placebo (PLO)+TAU arm across the 10-week treatment and follow-up periods. conditions: Stimulant Use Disorder studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Mirtazapine name: Placebo measure: Urinanalysis Verified Increased Days of MA Abstinence measure: Actigraphy Verified Improved Sleep Patterns measure: Self Reported Quantity of Adverse Events measure: Urinanalysis Verified Increased Days of Abstinence from Other Substances sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323824 id: 2000033271 id: CTN-0131 type: OTHER domain: Clinical Trials Network id: 5UG1DA015831-21 type: NIH link: https://reporter.nih.gov/quickSearch/5UG1DA015831-21 briefTitle: Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment. overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-12 date: 2029-05 date: 2024-03-21 date: 2024-03-21 name: Yale University class: OTHER name: National Institutes of Health (NIH) name: National Institute on Drug Abuse (NIDA) name: The Emmes Company, LLC name: University of California, San Francisco name: Boston Medical Center (BMC) name: Hennepin Healthcare Research Institute name: Alameda Health System name: Marshall Health name: Kaiser Permanente briefSummary: The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone. conditions: Opioid Use Disorder studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The comparative effectiveness of two strategies to address retention in medication for opioid use disorder (MOUD) treatment will be tested over a 168-day period. Behavioral treatments offered to patients are designed to be similar across the two medication conditions.
Office-based buprenorphine (BUP) where the clinician prescribes BUP formulations that are dispensed at a pharmacy or administered in the office (e.g., extended-release formulations). Providers and RCT participants will have flexibility to use behavioral and pharmacological services as clinically indicated. primaryPurpose: TREATMENT masking: NONE count: 600 type: ESTIMATED name: Methadone name: Buprenorphine (BUP) measure: Number of days of continuous treatment with study site clinician-prescribed methadone or buprenorphine, as randomized, during the 168 days post-randomization among RCT participants. measure: Number of self-reported days in any FDA-approved formulation of MOUD treatment (e.g., buprenorphine, methadone or naltrexone) during the 168 days post-randomization. measure: Number of self-reported days in formal OUD treatment, according to American Society of Addiction Medicine (ASAM) levels of care 1-4, during the 168 days post-randomization. measure: Number of days prescribed any FDA-approved MOUD formulation during the 168 days post-randomization. measure: Number of days of self-reported non-prescribed opioid use per month. measure: Number of days of self-reported non-prescribed stimulant use per month. measure: Number of days of self-reported non-prescribed benzodiazepine use per month. measure: Urine toxicology measure: Participant satisfaction with MOUD measure: Total number of self-reported overdose events per total number of participant days at risk. measure: Total number of self-reported injection drug use related events per total number of participant days at risk. measure: Pain measured using PEG-3: "Pain average," "interference with Enjoyment of life," and "interference with General activity." measure: Number of self-reported days with acute care utilization (ED or hospitalization) events during the 168 days post-randomization per month. sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323811 id: COPE CMR briefTitle: Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics acronym: COPE-CMR overallStatus: RECRUITING date: 2023-06-15 date: 2025-06-30 date: 2025-12-31 date: 2024-03-21 date: 2024-03-21 name: University of Zurich class: OTHER name: ETH Zurich briefSummary: This clinical study examines patients presenting with acute myocardial infarction and no significant coronary artery disease on coronary angiography (MINOCA) and patients with MINOCA-mimics with advanced CMR.
Participants will undergo advanced CMR imaging in the acute setting (within 10 days after event) and post convalescence (after 3 months). conditions: Myocardial Infarction With Non-Obstructive Coronary Artery conditions: Myocarditis Acute conditions: Takotsubo Cardiomyopathy conditions: Spontaneous Coronary Artery Dissection conditions: Non ST Elevation Myocardial Infarction studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 5 groups of patients (MINOCA, myocarditis, Takotsubo cardiomyopathy, SCAD, NSTEMI) will undergo CMR with 3D perfusion in the acute setting (within 10 days after the event) and post convalescence (after 3 months) primaryPurpose: DIAGNOSTIC masking: SINGLE whoMasked: INVESTIGATOR count: 75 type: ESTIMATED name: CMR measure: Myocardial perfusion reserve index measure: epicardial adipose tissue (EAT) measure: cardiovascular events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Zurich status: RECRUITING city: Zürich zip: 8091 country: Switzerland name: Robert Manka role: CONTACT lat: 47.36667 lon: 8.54999 hasResults: False